Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-UMIN000012862
JPRN-UMIN000012862
Completed
未知

Efficacy and pharmacokinetics study of erlotinib in patients with non-small cell lung cancer - Efficacy and pharmacokinetics study of erlotinib in patients with non-small cell lung cancer

Shizuoka cancer center0 sites70 target enrollmentStarted: January 16, 2014Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsAdvanced non-small cell lung cancer

Overview

Phase
未知
Status
Completed
Enrollment
70
OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
20years-old to ot applicable (—)
Sex
All

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • •Patients with interstitial pneumonitis identified by chest X\-ray

Investigators

Similar Trials

Completed
Not Applicable
Evaluation of efficacy of erlotinib in patients with untreated, EGFR mutation positive, untreated-locally advanced NSCLC.ntreated, EGFR mutation positive, untreated-locally advanced NSCLC.
JPRN-UMIN000011467agasaki Thoracic Oncology Group10
Completed
Not Applicable
[11C]Erlotinib pharmacokinetics: an in vivo study using positron emission tomography in non-small cell lung cancer patients with and without erlotinib therapy.lung cancernon-small cell lung carcinoma10038666
NL-OMON36826Vrije Universiteit Medisch Centrum10
Not yet recruiting
Phase 2
To evaluate the efficacy and safety of Erlotinib and Bevacizumab in patients with advanced Non-squamous Non-Small Cell Lung Cancer with brain metastasis who acquired resistance to prior EGFR-TKI treatment harboring EGFR mutation.on-Small-Cell Lung Cancer
JPRN-UMIN000012515Department of Respiratory Medicine, Kumamoto University Hospital16
Terminated
Phase 1
Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV InfectionHIV InfectionRecurrent Non-Small Cell Lung CarcinomaStage IIIA Non-Small Cell Lung CancerStage IIIB Non-Small Cell Lung CancerStage IV Non-Small Cell Lung Cancer
NCT02134886National Cancer Institute (NCI)48
Active, not recruiting
Not Applicable
Pharmacodynamic study of Erlotinib (Tarceva) in patients with mestastatic or locally advanced Epidermoid carcinoma of the head and neckMestastatic or locally advanced Epidermoid carcinoma of the head and neck
EUCTR2005-003814-14-ESnidad Integral de Investigación en Oncología, S.L.49